AW
KNSA icon

Avion Wealth’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Avion Wealth’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
45
+21
+88% +$1.09K ﹤0.01% 1078
2026
Q1 		$1K Hold
24
– – ﹤0.01% 1071
2025
Q4 		$0 Sell
24
-19
-44% -$762 ﹤0.01% 1424
2025
Q3 		$1K Hold
43
– – ﹤0.01% 1036
2025
Q2 		$1K Buy
+43
New +$1.09K ﹤0.01% 996

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Avion Wealth's KNSA Position: Q2 2026 in Review

Avion Wealth increased its Kiniksa Pharmaceuticals (KNSA) stake by 88% in Q2 2026, buying an estimated $1.09K and bringing the position to 45 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Avion Wealth first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Avion Wealth held 45 shares of Kiniksa Pharmaceuticals worth $2K as of Q2 2026.
  • Avion Wealth bought 21 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.09K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1078 holding.
  • Avion Wealth first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.